[New therapeutic options in renal diseases--hypotensive therapy].
Progression of a variety of chronic renal diseases may be largely due to secondary hemodynamic and metabolic factors, rather than the activity of the underlying disorder. Some of these factors can be treated, possibly preventing or minimizing further glomerular injury. An important component of this approach is antihypertensive therapy, particularly with angiotensin converting enzyme (ACE) inhibitors and, at least in patients with type 2 diabetes, angiotensin II receptor blockers. The clinical studies supporting importance of blood pressure control in diabetic and nondiabetic chronic renal diseases and recommended treatment goals will be presented here.
Gaciong
Zbigniew
Z
Katedra i Klinika Chor6b Wewnetrznych, Nadciśnienia Tetniczego i Angiologii AM w Warszawie.
D000804:Angiotensin II / Q000031:analogs & derivatives*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000150:complications; D006801:Humans; D006977:Hypertension, Renal / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D012307:Risk Factors
D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000804:Angiotensin II